NewsBenzingaDBV Technologies presenta ante la FDA la solicitud de licencia biológica (BLA) para el parche VIASKIN Peanut en niños de 4 a 7 años con alergia al cacahuete y solicita revisión prioritaria DBV Technologies presenta ante la FDA la solicitud de licencia biológica (BLA) para el parche VIASKIN Peanut en niños de 4 a 7 años con alergia al cacahuete y solicita revisión prioritaria Benzinga 2026.09.30 07:43 (GMT+0) Open on Benzinga Other news Deutsche Bank Initiates Coverage On FormFactor with Buy Rating, Announces Price Target of $200 SBI, Mesh, Money Forward to Form Japan Digital Asset Joint Venture Full Transcript: Rockwell Automation Q3 2026 Earnings Call Meta avoided billions in federal taxes by classifying its data centers as experimental facilities Coinbase Receives CFTC Approval to Operate a Derivatives Clearing Organization Piper Sandler Maintains Overweight on Microsoft, Raises Price Target to $610
